10 Ausgewählte Publikationen aus 145 peer-review Manuskripten:

1. Nwaeburu CC, Abukiwan A, Zhao Z, Herr I (2017). Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer. Molecular Cancer 16:23. IF₂₀₂₀ 27.401

 

2. Groth A, Salnikov AV, Ottinger S, Gladkich J, Liu L, Kallifatidis G, Salnikova O, Ryschich E, Giese N, Giese T, Momburg F, Büchler MW,Moldenhauer G, Herr I. (2012). New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody for tumor targeting. Clin Cancer Res, 18:1028. IF₂₀₂₀ 12.531

 

3. Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, Wirth T, Schemmer P, Büchler MW, Zöller M, Salnikov A, Herr I. (2010). Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res, 70:5004. IF₂₀₂₀12.701

 

4.  Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, Groth A, Mattern J, Li Z, Kolb A, Moldenhauer G, Altevogt P, Wirth T, Werner J, Schemmer P, Büchler MW, Salnikov AV, Herr I(2009). Sulforaphane targets pancreatic tumor-initiating cells by NF-kB-induced anti-apoptotic signaling. GUT, 58:949. IF₂₀₂₀ 23.059

 

5. Herr I, Schemmer P and Büchler MW. (2007). On the TRAIL to therapeutic intervention in liver disease. Hepatology 46:266. IF₂₀₂₀ 17.425

 

6. Herr I and Pfitzenmaier J (2006). Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol 7:425. IF₂₀₂₀ 41.316

 

7. Wenger T, Mattern J, Penzel R, Gassler N, Haas T, Sprick M, Walczak H, Krammer PH, Debatin K-M and Herr I (2006). Specific resistance uponlentiviral TRAIL transfer by intracellular retention of TRAIL receptors. Cell Death Differ 13:1740. IF₂₀₂₀ 10.717

 

8. Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer, PH, Knebel-Döberitz M and Debatin K-M (2003). Glucocorticoid co-treatment induces apoptosis resistance towards cancer therapy in carcinomas. Cancer Res 63:3112. IF₂₀₂₀ 12.701

 

9. Herr I, Wilhelm D, Boehler T, Angel P and Debatin K-M (1997). Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis.  EMBO J 16:6200. IF₂₀₂₀ 11.598

 

10. Friesen C*, Herr I* (*equal contribution), Krammer P and Debatin K-M (1996). Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis of leukemia cells.Nature Med 2: 574. IF₂₀₂₀ 53.44